These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

122 related items for PubMed ID: 621716

  • 1. Synthesis and antitumor activity of preactivated isophosphamide analogues bearing modified alkylating functionalities.
    Takamizawa A, Matsumoto S, Iwata T, Makino I, Yamaguchi K, Uchida N, Kasai H, Shiratori O, Takase S.
    J Med Chem; 1978 Feb; 21(2):208-14. PubMed ID: 621716
    [Abstract] [Full Text] [Related]

  • 2. Synthesis, stereochemistry and antitumor activity of 4-hydroperoxyisophosphamide (NSC-227114) and related compounds.
    Takamizawa A, Matsumoto S, Iwata T, Makino I.
    Chem Pharm Bull (Tokyo); 1977 Aug; 25(8):1877-91. PubMed ID: 562722
    [No Abstract] [Full Text] [Related]

  • 3. Stereochemistry, metabolism, and antitumor activity of 4-hydroperoxyisophosphamide (NSC-227114) and its stereoisomer.
    Takamizawa A, Iwata T, Yamaguchi K, Shiratori O, Harada M.
    Cancer Treat Rep; 1976 Apr; 60(4):361-8. PubMed ID: 1277212
    [Abstract] [Full Text] [Related]

  • 4. Synthesis and antitumor activity of analogues of ifosfamide modified in the N-(2-chloroethyl) group.
    Misiura K, Kinas RW, Stec WJ, Kusnierczyk H, Radzikowski C, Sonoda A.
    J Med Chem; 1988 Jan; 31(1):226-30. PubMed ID: 3336021
    [Abstract] [Full Text] [Related]

  • 5. Synthesis of 4-hydroperoxy derivatives of ifosfamide and trofosfamide by direct ozonation and preliminary antitumor evaluation in vivo.
    Hohorst HJ, Peter G, Struck RF.
    Cancer Res; 1976 Jul; 36(7 PT 1):2278-81. PubMed ID: 945124
    [Abstract] [Full Text] [Related]

  • 6. Enantioselective cytotoxic activity of bromine-substituted analogues of ifosfamide. A microsomal implication.
    Hładoń B, Sloderbach A, Laskowska H.
    Pol J Pharmacol; 1997 Jul; 49(2-3):127-36. PubMed ID: 9437759
    [Abstract] [Full Text] [Related]

  • 7. Comparative studies on biological activity of /+/R and /-/S enantiomers of cyclophosphamide and ifosfamide. I. Antitumour effect of cyclophosphamide and ifosfamide enantiomers.
    Paprocka M, Kuśnierczyk H, Budzyński W, Rak J, Radzikowski C.
    Arch Immunol Ther Exp (Warsz); 1986 Jul; 34(3):275-84. PubMed ID: 3592931
    [Abstract] [Full Text] [Related]

  • 8. Combination chemotherapy of 6-thioguanine with various antitumor agents against murine leukemia L-1210.
    Fujimoto S, Inagaki J, Horikoshi N, Hoshino A.
    Gan; 1977 Oct; 68(5):543-52. PubMed ID: 201534
    [Abstract] [Full Text] [Related]

  • 9. (S)-(-)-Bromofosfamide (CBM-11): synthesis and antitumor activity and toxicity in mice.
    Misiura K, Kinas RW, Kuśnierczyk H, Radzikowski C, Stec WJ.
    Anticancer Drugs; 2001 Jun; 12(5):453-8. PubMed ID: 11395573
    [Abstract] [Full Text] [Related]

  • 10. Isophosphoramide mustard, a metabolite of ifosfamide with activity against murine tumours comparable to cyclophosphamide.
    Struck RF, Dykes DJ, Corbett TH, Suling WJ, Trader MW.
    Br J Cancer; 1983 Jan; 47(1):15-26. PubMed ID: 6821629
    [Abstract] [Full Text] [Related]

  • 11. Antitumor activity evaluation of bromine-substituted analogues of ifosfamide. I. Stereodifferentiation of biological effects and selection of the most potent compounds.
    Glazman-Kuśnierczyk H, Matuszyk J, Radzikowski C.
    Immunopharmacol Immunotoxicol; 1992 Jan; 14(4):883-911. PubMed ID: 1294626
    [Abstract] [Full Text] [Related]

  • 12. Mutagenic and chemotherapeutic activity in L1210 leukemia of several monofunctional alkylating agents.
    Schmid FA, Otter GM, Mehta BM.
    Cancer Res; 1985 Jan; 45(1):40-4. PubMed ID: 3965147
    [Abstract] [Full Text] [Related]

  • 13. Absence of cross-resistance to alkylating agents in cyclophosphamide-resistant L1210 leukemia.
    Wampler GL, Regelson W, Bardos TJ.
    Eur J Cancer (1965); 1978 Sep; 14(9):977-82. PubMed ID: 710488
    [No Abstract] [Full Text] [Related]

  • 14. Synthesis and antitumor properties of activated cyclophosphamide analogues.
    Borch RF, Canute GW.
    J Med Chem; 1991 Oct; 34(10):3044-52. PubMed ID: 1920355
    [Abstract] [Full Text] [Related]

  • 15. Synthesis, in vitro metabolic studies, and antitumour activity of methyl analogues of ifosfamide.
    Misiura K, Kardacka K, Kusnierczyk H.
    Arch Pharm (Weinheim); 2001 Sep; 334(8-9):291-4. PubMed ID: 11688140
    [Abstract] [Full Text] [Related]

  • 16. Biologic activity of two derivatives and six possible metabolites of cyclophosphamide (NSC-26271).
    Lelieveld P, van Putten LM.
    Cancer Treat Rep; 1976 Apr; 60(4):373-9. PubMed ID: 1064468
    [Abstract] [Full Text] [Related]

  • 17. Comparison of cytotoxic action of iphosphamide and cyclophosphamide.
    Phelan ET, Vietti TJ, Valeriote FA, Coulter D.
    Anticancer Res; 1981 Apr; 1(3):149-54. PubMed ID: 7342853
    [Abstract] [Full Text] [Related]

  • 18. 1,2-bis(arylsulfonyl)hydrazines. 2. The influence of arylsulfonyl and aralkylsulfonyl substituents on antitumor and alkylating activity.
    Shyam K, Furubayashi R, Hrubiec RT, Cosby LA, Sartorelli AC.
    J Med Chem; 1986 Jul; 29(7):1323-5. PubMed ID: 3806585
    [Abstract] [Full Text] [Related]

  • 19. X-ray crystallographic studies of cyclophosphamide (NSC-26271) derivatives.
    Camerman A, Smith HW, Camerman N.
    Cancer Treat Rep; 1976 Apr; 60(4):517-22. PubMed ID: 1277229
    [Abstract] [Full Text] [Related]

  • 20. Anodic oxidation of ifosfamide and cyclophosphamide: a biomimetic metabolism model of the oxazaphosphorinane anticancer drugs.
    Paci A, Martens T, Royer J.
    Bioorg Med Chem Lett; 2001 May 21; 11(10):1347-9. PubMed ID: 11392552
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.